Top

Published in:

01-12-2011 | Review

Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management

Author: Rebecca L. Brown

Published in: Targeted Oncology | Issue 4/2011

Abstract

In recent years, tyrosine kinase inhibitors (TKIs) have emerged as a new class of anti-cancer therapy with proven efficacy in several types of carcinoma. Although generally considered less toxic than cytotoxic chemotherapy, TKIs do have significant side effects including fatigue and hypertension. In addition, TKI-induced thyroid dysfunction is now recognized as a common toxicity that is associated with some TKI inhibitors. Detection of TKI-induced thyroid dysfunction requires routine monitoring of thyroid function and, in some cases, may require treatment. This review provides a comprehensive assessment of literature evaluating TKI-induced thyroid dysfunction, focusing on the potential mechanisms that result in this toxicity, whether the development of thyroid dysfunction is clinically meaningful, and controversies regarding treatment with thyroid hormone therapy.

Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM (2007) Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99:81–83PubMedCrossRef

Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, Sugawara M, Hershman JM (2007) Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 17:351–355PubMedCrossRef

Schoeffski P WP, Himpe U, Dychter SS, Baum CM, Prenen H, Wildiers H, Bex M, Dumez H, (2006). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I Vol 24, No 18S (June 20 Supplement), 2006:3092

Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK (2006) Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145:660–664PubMed

Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, Beck-Peccoz P, Fugazzola L (2007) A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 92:3531–3534PubMedCrossRef

Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, Schoffski P (2008) The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 99:448–454PubMedCrossRef

Tamaskar I, Bukowski R, Elson P, Ioachimescu AG, Wood L, Dreicer R, Mekhail T, Garcia J, Rini BI (2008) Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol 19:265–268PubMedCrossRef

Clement P WP, Stefan C, Decallonne B, Dumez H, Wildiers H, Schöffski P(2008) J Clin Oncol 26 (May 20 suppl; abstr 16145)

de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, de Vries MM, Links TP, Lips CJ, Voest EE (2007) A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 92:3466–3469PubMedCrossRef

10.

de Groot JW, Zonnenberg BA, Plukker JT, van Der Graaf WT, Links TP (2005) Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther 78:433–438PubMedCrossRef

11.

Dora JM, Leie MA, Netto B, Fogliatto LM, Silla L, Torres F, Maia AL (2008) Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients. Eur J Endocrinol 158:771–772PubMedCrossRef

12.

Weisberg E, Catley L, Wright RD, Moreno D, Banerji L, Ray A, Manley PW, Mestan J, Fabbro D, Jiang J, Hall-Meyers E, Callahan L, DellaGatta JL, Kung AL, Griffin JD (2007) Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood 109:2112–2120PubMedCrossRef

13.

Manley PW, Drueckes P, Fendrich G, Furet P, Liebetanz J, Martiny-Baron G, Mestan J, Trappe J, Wartmann M, Fabbro D (2010) Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 1804:445–453PubMed

14.

Kim TD, Schwarz M, Nogai H, Grille P, Westermann J, Plockinger U, Braun D, Schweizer U, Arnold R, Dorken B, le Coutre P (2010) Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. Thyroid 20:1209–1214PubMedCrossRef

15.

Yoshizato T, Nannya Y, Yoshiki Y, Nakamura F, Imai Y, Ichikawa M, Kurokawa M (2011) Nilotinib-induced hypothyroidism in a patient with chronic myeloid leukemia. Int J Hematol 93:400–402PubMedCrossRef

16.

Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ (2008) Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359:31–42PubMedCrossRef

17.

Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Vasselli JR, Read J, Schlumberger M (2010) Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): a randomized, double-blind phase III trial (ZETA). J Clin Oncol 28 (Suppl; abstr 5503)CrossRef

18.

Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R (2010) Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 95:2664–2671PubMedCrossRef

19.

Kelly RJ, Rixe O (2010) Axitinib (AG-013736). Recent Results Cancer Res 184:33–44PubMedCrossRef

20.

Fujiwara Y, Kiyota N, Chayahara N, Suzuki A, Umeyama Y, Mukohara T, Minami H (2011) Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. Investig New Drugs. doi:10.1007/s10637-011-9637-1

21.

Wolter P SC, Decallonne B, Dumez H, Fieuws S, Wildiers H, Clement P, Debaere D, Van Oosterom A, and Schoffski P (2008) Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC). J Clin Oncol 26 (May 20 suppl; abstr 16145)

22.

Sato S, Muraishi K, Tani J, Sasaki Y, Tokubuchi I, Tajiri Y, Yamada K, Suekane S, Miyajima J, Matsuoka K, Hiromatsu Y (2010) Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma. Endocr J 57:873–880PubMedCrossRef

23.

Grossmann M, Premaratne E, Desai J, Davis ID (2008) Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) 69:669–672CrossRef

24.

Sakurai K, Fukazawa H, Arihara Z, Yoshida K (2010) Sunitinib-induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume. Tohoku J Exp Med 222:39–44PubMedCrossRef

25.

Rogiers A, Wolter P, Op de Beeck K, Thijs M, Decallonne B, Schoffski P (2010) Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction? Thyroid 20:317–322PubMedCrossRef

26.

Viglietto G, Romano A, Manzo G, Chiappetta G, Paoletti I, Califano D, Galati MG, Mauriello V, Bruni P, Lago CT, Fusco A, Persico MG (1997) Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization. Oncogene 15:2687–2698PubMedCrossRef

27.

Yamada E, Yamazaki K, Takano K, Obara T, Sato K (2006) Iodide inhibits vascular endothelial growth factor-A expression in cultured human thyroid follicles: a microarray search for effects of thyrotropin and iodide on angiogenesis factors. Thyroid 16:545–554PubMedCrossRef

28.

Jebreel A, England J, Bedford K, Murphy J, Karsai L, Atkin S (2007) Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int J Exp Pathol 88:271–277PubMedCrossRef

29.

Hoffmann S, Hofbauer LC, Scharrenbach V, Wunderlich A, Hassan I, Lingelbach S, Zielke A (2004) Thyrotropin (TSH)-induced production of vascular endothelial growth factor in thyroid cancer cells in vitro: evaluation of TSH signal transduction and of angiogenesis-stimulating growth factors. J Clin Endocrinol Metab 89:6139–6145PubMedCrossRef

30.

Baffert F, Le T, Sennino B, Thurston G, Kuo CJ, Hu-Lowe D, McDonald DM (2006) Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol 290:H547–H559PubMedCrossRef

31.

Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O’Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM (2006) VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290:H560–H576PubMedCrossRef

32.

Salem AK, Fenton MS, Marion KM, Hershman JM (2008) Effect of sunitinib on growth and function of FRTL-5 thyroid cells. Thyroid 18:631–635PubMedCrossRef

33.

Williams KJ, Telfer BA, Shannon AM, Babur M, Stratford IJ, Wedge SR (2007) Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit. Mol Cancer Ther 6:599–606PubMedCrossRef

34.

Alexandrescu DT, Popoveniuc G, Farzanmehr H, Dasanu CA, Dawson N, Wartofsky L (2008) Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies. Thyroid 18:809–812PubMedCrossRef

35.

Illouz F, Laboureau-Soares S, Dubois S, Rohmer V, Rodien P (2009) Tyrosine kinase inhibitors and modifications of thyroid function tests: a review. Eur J Endocrinol 160:331–336PubMedCrossRef

36.

Rivas M, Santisteban P (2003) TSH-activated signaling pathways in thyroid tumorigenesis. Mol Cell Endocrinol 213:31–45PubMedCrossRef

37.

Calebiro D, de Filippis T, Lucchi S, Martinez F, Porazzi P, Trivellato R, Locati M, Beck-Peccoz P, Persani L (2006) Selective modulation of protein kinase A I and II reveals distinct roles in thyroid cell gene expression and growth. Mol Endocrinol 20:3196–3211PubMedCrossRef

38.

Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G (2009) Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 6:219–228PubMedCrossRef

39.

Novartis Pharmaceuticals Corporation (2010) Gleevec (imatinib mesylate): full prescribing information. Novartis Pharmaceuticals Corporation, East Hanover

40.

Shinohara N TM, Kamishima T, Ikushima H, Sazawa A, Kanayama H, Nonomura K (2009) Efficacy and thyroidal effects of sunitinib in Japanese patients with metastatic renal cell carcinoma: hypothyroidism and thyroid atrophy as potential biomarkers for sunitinib? J Clin Oncol 27 (suppl; abstr e16097)

41.

Schmidinger M, Vogl UM, Bojic M, Lamm W, Heinzl H, Haitel A, Clodi M, Kramer G, Zielinski CC (2011) Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer 117:534–544PubMedCrossRef

42.

Riesenbeck LM, Bierer S, Hoffmeister I, Kopke T, Papavassilis P, Hertle L, Thielen B, Herrmann E (2010) Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World J Urol. doi:10.1007/s00345-010-0627-2

43.

Garfield D, Hercbergs A, Davis P (2007) Unanswered questions regarding the management of sunitinib-induced hypothyroidism. Nat Clin Pract 4:674CrossRef

44.

Theodossiou C, Skrepnik N, Robert EG, Prasad C, Axelrad TW, Schapira DV, Hunt JD (1999) Propylthiouracil-induced hypothyroidism reduces xenograft tumor growth in athymic nude mice. Cancer 86:1596–1601PubMedCrossRef

45.

Goodman AD, Hoekstra SJ, Marsh PS (1980) Effects of hypothyroidism on the induction and growth of mammary cancer induced by 7,12-dimethylbenz(a)anthracene in the rat. Cancer Res 40:2336–2342PubMed

46.

Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M, Hsu L, Krishnamurthy S, Theriault RL, Hortobagyi GN (2005) Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 103:1122–1128PubMedCrossRef

47.

Hercbergs AA, Goyal LK, Suh JH, Lee S, Reddy CA, Cohen BH, Stevens GH, Reddy SK, Peereboom DM, Elson PJ, Gupta MK, Barnett GH (2003) Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study. Anticancer Res 23:617–626PubMed

48.

Nelson M, Hercbergs A, Rybicki L, Strome M (2006) Association between development of hypothyroidism and improved survival in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 132:1041–1046PubMedCrossRef

49.

Gharib H, Tuttle RM, Baskin HJ, Fish LH, Singer PA, McDermott MT (2004) Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. Endocr Pract 10:497–501PubMed

50.

Fatourechi V (2009) Subclinical hypothyroidism: an update for primary care physicians. Mayo Clin Proc 84:65–71PubMedCrossRef

51.

Feldman DR, Martorella AJ, Robbins RJ, Motzer RJ (2007) Re: hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Nat Cancer Inst 99:974–975, author reply 976–977PubMedCrossRef

52.

Dedecjus M, Kolomecki K, Brzezinski J, Adamczewski Z, Tazbir J, Lewinski A (2007) Influence of L-thyroxine administration on poor-platelet plasma VEGF concentrations in patients with induced short-term hypothyroidism, monitored for thyroid carcinoma. Endocr J 54:63–69PubMedCrossRef

53.

Bladou F GG, Sabatier R, Deville J, Walz J, Narbonne H, Marcy M, Salem N, Brunelle S, Eymard J (2010) Hypothyroidism and survival during sunitinib therapy in metastatic renal cell carcinoma (mRCC): a prospective observational analysis. J Clin Oncol 28 (suppl; abstr e15013)

Title: Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management
Author: Rebecca L. Brown
Publication date: 01-12-2011
Publisher: Springer-Verlag
Published in: Targeted Oncology / Issue 4/2011
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-011-0197-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2011

Posterior reversible encephalopathy syndrome induced by anti-VEGF agents

Heart to heart with trastuzumab: a review on cardiac toxicity

Pulmonary toxicities from targeted therapies: a review

Hematologic toxicities of small molecule tyrosine kinase inhibitors

The carriages to the good drivers

Cardiovascular toxicity of anti-angiogenic drugs

Keynote webinar | Spotlight on antibody–drug conjugates in cancer